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Background: The kidney-brain interaction has been a topic of growing interest. Past studies of the effect of
kidney function on intracerebral hemorrhage (ICH) outcomes have yielded inconsistent findings. Although the
second, main phase of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial
(INTERACT2) suggests the effectiveness of early intensive blood pressure (BP) lowering in improving
functional recovery after ICH, the balance of potential benefits and harms of this treatment in those with
decreased kidney function remains uncertain.
Study Design: Secondary analysis of INTERACT2, which randomly assigned patients with ICH with
elevated systolic BP (SBP) to intensive (target SBP, 140 mm Hg) or contemporaneous guideline-based
(target SBP, 180 mm Hg) BP management.
Setting & Participants: 2,823 patients from 144 clinical hospitals in 21 countries.
Predictors: Admission estimated glomerular filtration rates (eGFRs) of patients were categorized into 3
groups based on the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation:
normal or high, mildly decreased, and moderately to severely decreased (.90, 60-90, and ,60 mL/min/
1.73 m2, respectively).
Outcomes: The effect of admission eGFR on the primary outcome of death or major disability at 90 days
(defined as modified Rankin Scale scores of 3-6) was analyzed using a multivariable logistic regression model.
Potential effect modification of intensive BP lowering treatment by admission eGFR was assessed by inter-
action terms.
Results: Of 2,623 included participants, 912 (35%) and 280 (11%) had mildly and moderately/severely
decreased eGFRs, respectively. Patients with moderately/severely decreased eGFRs had the greatest risk for
death or major disability at 90 days (adjusted OR, 1.82; 95% CI, 1.28-2.61). Effects of early intensive BP
lowering were consistent across different eGFRs (P5 0.5 for homogeneity).
Limitations: Generalizability issues arising from a clinical trial population.
Conclusions: Decreased eGFR predicts poor outcome in acute ICH. Early intensive BP lowering provides
similar treatment effects in patients with ICH with decreased eGFRs.
Am J Kidney Dis. 68(1):94-102. ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National
Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://
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Estimated GFR and ICH Outcomesprognostic signiﬁcance of kidney function in patients
with acute intracerebral hemorrhage (ICH), the most
serious type of stroke, remains uncertain. Although
the second, main phase of the Intensive Blood Pres-
sure Reduction in Acute Cerebral Hemorrhage Trial
(INTERACT2) did not demonstrate a signiﬁcant
reduction in the combined primary outcome of 90-day
death or major disability by intensive blood pressure
(BP) treatment at the conventional P , 0.05 level, it
showed improved secondary functional recovery, as
measured by changes across all levels of the modiﬁed
Rankin Scale (mRS) scores. These ﬁndings have led
to revisions of guidelines,5,6 but concerns persist over
the potential for harm from such treatment (eg, in
patients with poor kidney function). The objectives
of this study were to elucidate the prognostic signi-
ﬁcance of decreased eGFR in more than 2,600
participants in INTERACT25 and assess whether
it modiﬁes the treatment effect of early intensive
BP lowering.
METHODS
Study Design and Patient Characteristics
This was a post hoc analysis of the INTERACT2 study popu-
lation, the details of which are outlined elsewhere.5 In brief,
INTERACT2 was an international, multicenter, open, blinded end
point–assessed, randomized, controlled trial involving 2,839 pa-
tients with acute spontaneous ICH within 6 hours of onset and
elevated systolic BP (SBP; 150-220 mm Hg). Participants were
randomly assigned to receive intensive (target SBP , 140 mm Hg
within 1 hour) or contemporaneous guideline-recommended
(target SBP , 180 mm Hg) BP-lowering therapy using locally
available agents according to standardized protocols. Patients were
excluded if they had a structural cerebral cause for the ICH, were
in a deep coma (deﬁned as Glasgow Coma Scale scores of 3-5),
had a massive ICH with an expected poor prognosis, or early
surgery to evacuate the hematoma was planned. The study pro-
tocol was approved by an appropriate ethics committee at each
hospital site, and written informed consent was obtained from each
participant or his or her legal surrogate.
Demographic and clinical characteristics were recorded at the
time of enrollment. Initial laboratory parameters, including serum
creatinine, were measured at hospital presentation/admission.
Assessment of kidney function was based on eGFR calculated
using the CKD-EPI (CKD Epidemiology Collaboration) creatinine
equation.7 Because creatinine level was not standardized to
isotope-dilution mass spectrometry, the INTERACT2 creatinine
level was reduced by 5% for calculations using the CKD-EPI
equation.8 Participants were categorized into 3 groups of eGFRs:
normal or high, mildly decreased, and moderately to severely
decreased (.90, 60-90, and ,60 mL/min/1.73 m2, respectively).9
BP was measured in the nonparetic arm with the patient supine
using an automated device or manual sphygmomanometer with an
appropriate size cuff. Baseline BP was measured twice with an
interval of 2 or fewer minutes and the mean of the 2 measurements
was used. Achieved BP in the hyperacute phase was measured
at 1, 6, 12, 18, and 24 hours postrandomization; mean values of
these 5 measurements were calculated. A diagnostic computed
tomographic (CT) scan was obtained for all participants according
to standardized techniques at baseline and at a mean of 24 6 3
(standard deviation) hours in a subset of patients where this was
routine or for a substudy evaluating hematoma growth. For eachAm J Kidney Dis. 2016;68(1):94-102CT scan, uncompressed digital CT images were collected in
Digital Imaging and Communications in Medicine (DICOM)
format on a CD-ROM identiﬁed only with the patient’s unique
study number. Hematoma and perihematomal edema volumes
were independently assessed by trained neurologists (S.S., C.D.,
Y.C.) who were blinded to clinical and treatment details and date
and sequence of scan using computer-assisted multislice plani-
metric and voxel threshold techniques.10,11
Outcomes
For these analyses, the primary clinical outcome was death or
major disability at 90 days (deﬁned by mRS scores of 3-6).12
Secondary clinical outcomes were, separately, death and major
disability (mRS scores of 6 and 3-5, respectively) at 90 days. CT
outcomes in a subset of patients were absolute 24-hour hematoma
and perihematomal edema growth volumes.
Statistical Analysis
Baseline characteristics of patients in predeﬁned groups were
summarized as mean 6 standard deviation or median with inter-
quartile range for continuous variables and as number (percent) for
categorical variables, with comparisons made using Wilcoxon or
c2 tests. Associations between baseline eGFR and clinical out-
comes were examined using categorical and ordinal logistic
regression, using normal or high eGFR as the reference group and
adjusted for potential confounders including: age, Chinese region,
any history of ischemic stroke, acute coronary syndrome, hyper-
tension, diabetes mellitus, prior use of antithrombotics and a statin,
log-transformed time from onset to randomization, baseline SBP,
baseline National Institutes of Health Stroke Scale score (,14
and$14), baseline hematoma volume (#10, 11-20, and.20 mL),
location (lobar and nonlobar) of ICH, intraventricular extension of
ICH, and randomly assigned group. We further tested potential
effect modiﬁcation by antithrombotic therapy on the relationship
between kidney function and the primary outcome using interac-
tion terms. Stratiﬁed analyses of antithrombotic users versus non–
antithrombotic users were also carried out in logistic regression
models. Heterogeneity of the treatment effect of intensive BP
lowering between eGFR groups was also examined with the use of
interaction terms. Effects of eGFR levels on mean achieved SBP
during the initial 24 hours in each treatment arm were assessed by
analysis of covariance adjusted for the same covariates except for
randomized intensive BP lowering. The association between eGFR
and 24-hour absolute growth of hematoma and perihematomal
edema volumes was also determined using analysis of covariance;
the 24-hour hematoma growth model was adjusted for recurrent
ICH, warfarin use, time from onset to baseline CT scan, catego-
rized baseline hematoma volume, and intraventricular extension of
ICH.10 The 24-hour perihematomal edema growth model was
adjusted for time from onset to CT scan, categorized baseline ICH
volume, intraventricular extension of ICH, and 24-hour hematoma
growth.11 Data are reported as odds ratios (ORs) and 95% conﬁ-
dence intervals (CIs). A 2-tailed P, 0.05 was regarded as indi-
cating statistical signiﬁcance. All analyses were performed using
SAS software (version 9.3; SAS Institute Inc).
RESULTS
A total of 2,623 patients with recorded admission
creatinine level and 90-day clinical outcome were
included in this study (Fig S1, available as online
supplementary material). Characteristics for those
included and excluded were broadly similar
(Table S1). Of those included, 1,431 (55%), 912
(35%), and 280 (11%) patients had normal/high,
mildly decreased, and moderately/severely decreased95
Zheng et aleGFR, respectively. There were 9 patients who
had received dialysis within 7 days of the hospital
admission. In comparison to those with normal/high
eGFRs, patients with decreased eGFRs tended to be
older and were recruited from countries outside
China. Patients with decreased eGFRs were more
likely to have had a history of ischemic stroke, acute
coronary syndrome, hypertension, and diabetesTable 1. Patient Characteristics Accord
Normal or High eGFR:
.90 mL/min/1.73 m2
No. of patients 1,431
Demographics
Age, y 59 6 11
Male sex 900 (63)
Ethnicity
Chinese ethnicity 1,073 (75)
African ethnicity 16 (1)
Medical history
ICH 118 (8)
Ischemic stroke 130 (9)
Acute coronary syndrome 27 (2)
Hypertension 1,020 (71)
Diabetes mellitus 125 (9)
Medications
Antihypertensives 566 (40)
Antithrombotics 105 (7)
Statin 65 (5)
Clinical features
Time from onset to randomization, h:min 3:41 [2:45-4:44]
SBP, mm Hg 1786 16
DBP, mm Hg 1036 14
ICH score 1 (0-1)
NIHSS$ 14a 444 (31)
GCS# 9b 101 (7)
Serum creatinine, mg/dL 0.656 0.15
Baseline CT findings
Hematoma volume, mLc 11.5 [6.1-19.8]
Hematoma locationd
Lobar 108 (8)
Deep 1,113 (85)
Brainstem 46 (4)
Cerebellum 43 (3)
Intraventricular extension of ICHc 329 (25)
Perihematomal edema volume, mLe 1.8 [0.9-3.6]
Randomized intensive BP lowering 708 (49)
Treatment with $2 BP-lowering agents 645 (45)
Note: Values for categorical variables are given as number (perc
deviation or median [interquartile range].
Abbreviations: BP, blood pressure; CT, computed tomography; DB
rate; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; N
blood pressure.
aNIHSS scores can range from 0 (normal, no neurologic deficit) to
bGCS scores can range from 3 (deep coma) to 15 (normal, alert).
cThere were 195 total patients with missing baseline CT data.
dThere were 207 total patients with missing information for baselin
eThere were 1,827 total patients with missing information for base
96mellitus and to have used antithrombotics and statins
prior to ICH. Furthermore, they had higher SBP,
National Institutes of Health Stroke Scale score, and
ICH score values, with a greater proportion of intra-
ventricular extension of ICH at admission and
required a higher number of BP-lowering agents
compared with patients with normal/high eGFRs
(Table 1).ing to Admission eGFR Categories
Mildly Decreased eGFR:
60-90 mL/min/1.73 m2
Moderately/Severely Decreased
eGFR: ,60 mL/min/1.73m2 P
912 280
70 6 12 71 6 14 ,0.001
568 (62) 172 (61) 0.9
518 (57) 154 (55) ,0.001
8 (1) 4 (1) 0.7
70 (8) 26 (9) 0.7
105 (12) 28 (10) 0.2
34 (4) 15 (5) 0.001
663 (73) 223 (80) 0.02
108 (12) 54 (19) ,0.001
468 (51) 161 (58) ,0.001
160 (18) 61 (22) ,0.001
97 (11) 32 (11) ,0.001
3:47 [2:54-4:42] 3:38 [2:53-4:44] 0.6
1806 17 183 6 18 ,0.001
99 6 15 100 6 16 ,0.001
1 (0-2) 1 (0-2) ,0.001
315 (35) 119 (43) ,0.001
87 (10) 26 (9) 0.08
0.89 6 0.17 1.90 6 1.60 ,0.001
10.0 [5.0-18.7] 10.5 [5.8-19.6] 0.04
0.03
108 (13) 28 (11)
692 (81) 206 (81)
22 (3) 8 (3)
30 (4) 12 (5)
261 (31) 92 (36) ,0.001
1.8 [0.8-3.7] 2.4 [1.0-4.9] 0.1
453 (50) 132 (47) 0.7
448 (49) 145 (52) 0.04
entage); values for continuous variables, as mean 6 standard
P, diastolic blood pressure; eGFR; estimated glomerular filtration
IHSS, National Institutes of Health Stroke Scale; SBP, systolic
42 (coma with quadriplegia).
e hematoma location.
line perihematomal edema volume.
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Estimated GFR and ICH OutcomesAdmission eGFR was associated with the primary
combined clinical outcome of death or major
disability and with the secondary clinical outcome of
major disability alone. Compared with patients with
normal/high eGFRs, those with moderately/severely
decreased eGFRs had worse 90-day outcomes
(adjusted OR, 1.82; 95% CI, 1.28-2.61; Table 2;
Fig 1) and greater risk for major disability (adjusted
OR, 1.51; 95% CI, 1.12-2.05; Table 2). However,
moderately/severely decreased eGFR was not signi-
ﬁcantly associated with death (adjusted OR, 1.08;
95% CI, 0.70-1.67; Table 2). Ordinal logistic regres-
sion analyses using all levels of mRS scores12 showed
similar results (adjusted OR, 1.49; 95% CI, 1.15-1.93
for moderately/severely decreased eGFRs; P for
trend 5 0.01; Fig 1). Furthermore, our results did not
show evidence of effect modiﬁcation by antith-
rombotic use for the primary outcome of death or
major disability (P 5 0.6). Stratiﬁed analyses
revealed statistically signiﬁcant associations between
admission eGFR and the primary outcome of death
and major disability among non–antithrombotic users
and associations for outcomes of death and major
disability separately among antithrombotic users
(Table S2).
There was no evidence of heterogeneity in the ef-
fect of early intensive BP-lowering treatment on the
primary poor outcome (death or major disability at 90
days) across the 3 eGFR groups (P 5 0.5 for homo-
geneity; Fig 2). Table S3 shows a signiﬁcant inverse
trend between mean achieved 24-hour SBP andTable 2. Association Between Admission e
Outcome/Admission eGFR No. of Events (%)
Death or major disability
Normal or high eGFRa 661/1,431 (46) 1.
Mildly decreased eGFRb 529/912 (58) 1.
Moderately/severely decreased eGFRc 200/280 (71) 2.
Death
Normal or high eGFRa 124/1,431 (9) 1.
Mildly decreased eGFRb 138/912 (15) 1.
Moderately/severely decreased eGFRc 49/280 (18) 2.
Major disability
Normal or high eGFRa 537/1,431 (38) 1.
Mildly decreased eGFRb 391/912 (43) 1.
Moderately/severely decreased eGFRc 151/280 (54) 1.
Abbreviations: CI, confidence interval; eGFR; estimated glomerula
aeGFR .90 mL/min/1.73 m2.
beGFR of 60-90 mL/min/1.73 m2.
ceGFR ,60 mL/min/1.73 m2.
dAdjusted for age, Chinese ethnicity, history of ischemic stroke, acu
of antithrombotics and statin, log-transformed time from onset to ran
Institutes of Health Stroke Scale score (,14 and $14), hematoma
lobar), intraventricular extension of intracerebral hemorrhage, and ra
Am J Kidney Dis. 2016;68(1):94-102categories of eGFR in the treatment group (P for
trend , 0.001).
A substantial number of patients were missing 24-
hour CT imaging data. There were 923 patients with
available hematoma growth data and 798 with peri-
hematomal edema growth data (Fig S1). As shown in
Table S4, there is no signiﬁcant association between
decreased eGFR and 24-hour hematoma and peri-
hematomal edema growth (adjusted P for trend 5 0.3
for both).
DISCUSSION
This study shows that reduced kidney function on
admission is an independent predictor of poor
outcome in patients with acute ICH, but this does not
appear to be due to an effect of hematoma or peri-
hematomal edema growth. However, there was no
evidence of heterogeneity in the beneﬁcial effect of
early intensive BP lowering according to different
eGFRs.
There is increasing awareness of the inﬂuence
of kidney function on the outcome from acute stroke,2-
4,13,14 with previous studies being largely consistent in
showing that reduced kidney function has independent
signiﬁcance in ischemic or undifferentiated stroke.2-4
However, studies of the relationship between kidney
function and outcomes in ICH are limited.14-18 A
multicenter study of 113,059 patients with ICH in the
United States reported an association between kidney
dysfunction and higher in-hospital mortality,18
which conﬁrmed results of other small studies of thisGFR and Clinical Outcomes at 90 Days
Univariable Multivariable
OR (95% CI) P for trend OR (95% CI) P for trend
00 (reference) ,0.001 1.00 (reference) 0.007d
61 (1.36-1.90) 1.04 (0.83-1.31)
91 (2.20-3.85) 1.82 (1.28-2.61)
00 (reference) ,0.001 1.00 (reference) 0.8d
88 (1.45-2.43) 0.96 (0.69-1.34)
24 (1.56-3.20) 1.08 (0.70-1.67)
00 (reference) ,0.001 1.00 (reference) 0.03d
25 (1.06-1.48) 1.01 (0.82-1.24)
95 (1.51-2.52) 1.51 (1.12-2.05)
r filtration rate; OR, odds ratio.
te coronary syndrome, hypertension, diabetes mellitus, prior use
domization, baseline systolic blood pressure, baseline National
volume (#10, 11-20, and .20 mL) and location (lobar and non-
ndomly assigned group.
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0% 20% 40% 60% 80% 100%
0 1 2 3 4 5 6
Normal or high 
eGFRa (n=1431)
Mild decrease in 
eGFRb (n=912)
Moderate-severe decrease
in  eGFRc (n=280)
mRS score
Patients
0 1 2 3 4 65
Figure 1. Baseline estimated glomerular filtration rate (eGFR) and modified Rankin Scale (mRS) score at 90 days. Crude odds
ratios (ORs) of ordinal logistic regression analysis, 1.65 (95% confidence interval [CI], 1.43-1.92) for group with mildly decreased
eGFR; and 2.58 (95% CI, 2.05-3.24) for the group with moderately/severely decreased eGFR in comparison to the normal- or
high-eGFR group (P for trend , 0.001). Adjusted ORs of ordinal logistic regression analysis, 1.04 (95% CI, 0.88-1.23) for the group
with mildly decreased eGFR; and 1.49 (95% CI, 1.15-1.93) for the group with moderately/severely decreased eGFR in comparison to
thw normal- or high-eGFR group (P for trend 5 0.01). a .90 mL/min/1.73 m2. b60-90 mL/min/1.73 m2. c,60 mL/min/1.73 m2.
Zheng et altopic.14-17 Nonetheless, these studies did not include
data related to imaging ﬁndings16-18 or functional
outcome14,15,18 and lacked the ability to fully adjust
for confounding variables due to small sample
sizes.14-17 Our study largely overcomes these
limitations by being based on a large population of
well-characterized patients from a wide range of
hospitals across 21 countries, and we also adjusted
for various important confounders, such as ICH vol-
ume, ICH location, and baseline clinical status, that
are components of the predictive ICH and the Func-
tional Outcome in Patients with Primary Intracerebral
Hemorrhage (FUNC) scores,19,20 thus strengthening
the evidence of an association between reduced kidney
function and poor functional outcome in ICH.0
eGFR
Number of outcomes / patients (%)
Intensive           Guidelines
Normal or high
(>90 mL/min/1.73m2)
Mild decrease
(60-90 mL/min/1.73m2)
Moderate-severe decrease
(<60 mL/min/1.73m2)
Overall
310/708 (44)             351/723 (49)
263/453 (58)             266/459 (58)
93/132 (70)               107/148 (72)
666/1293 (52)           724/1330 (54)
Figure 2. Effect of early intensive blood pressure lowering on dea
filtration rate (eGFR). Solid boxes represent estimates of treatment e
estimate of the effect; areas of the boxes are proportional to the recip
95% confidence interval (CIs); diamonds, estimates and 95% CIs for
Pressure Reduction in Acute Cerebral Hemorrhage Trial) had a repor
primary outcome of death or major disability with intensive treatmen
modified Rankin Scale scores with intensive treatment (OR for grea
98The exact mechanisms underlying the relationship
between reduced kidney function and poor outcomes
after stroke are unknown, although some studies have
proposed that it relates to effects on the initial size and
growth of hematoma and perihematomal edema.15,17
However, we have been unable to show a signiﬁ-
cant association between eGFR and 24-hour growth
in hematoma and perihematomal edema volume.
Because patients with decreased eGFRs are generally
older, premorbid frailty related to aging is a plausible
contributing factor to poor outcomes irrespective of
ICH dynamics.21,22 Other explanations include mea-
sures of brain frailty such as mild cognitive impair-
ment and co-occurring depression, which is common
in patients with CKD due to their high symptom0.83 (0.67-1.02)
1.00 (0.77-1.31)
0.89 (0.76-1.04)
0.91 (0.54-1.54)
1.5 2
Favors
guidelines
Favors
intensive
P for 
homogeneity
Odds ratio (95% CI)
0.5
th or major disability at 90 days by baseline estimated glomerular
ffect on risk for outcomes. Centers of the boxes are placed at the
rocal of the variance of the estimates. Horizontal lines represent
overall effects in total participants. INTERACT2 (Intensive Blood
ted odds ratio (OR) of 0.87 (95% CI, 0.75-1.01; P5 0.06) for the
t. Ordinal logistic regression analysis showed significantly lower
ter disability, 0.87; 95% CI, 0.77-1.00; P5 0.04).5
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Estimated GFR and ICH Outcomesburden and poor quality of life,23,24 that could
adversely affect rehabilitation potential and functional
outcomes after stroke.25-27 Prior studies have also
shown that receiving maintenance hemodialysis is an
independent indicator for poor functional outcome
and mortality after stroke, possibly related to the
presence of other comorbid conditions.28,29 Finally,
decreased erythropoietin production leading to ane-
mia in patients with CKD30 may contribute to
secondary cerebral injury caused by neuronal
tissue hypoxia, metabolic distress, and cell energy
dysfunction.31,32
Decreased eGFR is a surrogate marker of cerebral
small-vessel disease and is strongly associated with
vascular risk factors.1,33 We speculated that moder-
ately/severely decreased eGFR indicates altered cere-
bral regulation from more advanced cerebral
small-vessel disease.1,23-35 In patients with stable ce-
rebral autoregulation, decreases in cerebral perfusion
pressure trigger compensatory vasodilation of resis-
tance arterioles to preserve cerebral blood ﬂow.36
Conversely, autoregulatory failure may occur at
higher cerebral perfusion pressures in patients with
long-standing hypertension with altered cerebral
autoregulation.36 In the present analysis, the overall
treatment effect was homogeneous across all eGFRs
and the data do not show a deleterious effect of inten-
sive BP lowering in groups with decreased eGFRs.
Thus, our study supports ﬁndings of no relationship
between the magnitude of BP reduction and peri-
hematomal cerebral blood ﬂow in patients with mod-
erate ICH.37 Intriguingly, the beneﬁcial effect of
intensive BP lowering appears to be marginally more
pronounced in the group with normal or high eGFRs.
This trend may be attributed to variations in achieved
SBP during the initial 24 hours between eGFR groups
due to possible BP treatment resistance in patients with
decreased eGFRs (as evidenced by the higher number
of BP-lowering agents required)38,39 and/or more
cautious BP reduction management by physicians in
more vulnerable patients.
We recognize that this study has some limitations,
such as the inability to obtain information for kidney-
speciﬁc factors, for example, proteinuria prior to ICH
onset. Information for possible causes of poor ICH
outcomes in patients with decreased eGFRs, such as
premorbid physical and cognitive function, depres-
sion symptoms, and baseline hemoglobin levels or
anemia condition, was also unavailable. Due the
limited number of hemodialysis patients in the study,
we were also unable to assess its contribution to the
prognosis of ICH. Furthermore, the present study
includes patients from around the world and thus the
CKD-EPI equation, which was developed using a
sample of North American and European popula-
tions, may have led to overestimation of baselineAm J Kidney Dis. 2016;68(1):94-102kidney function measurements (especially in the
Asian population) and biased results toward the
null. Finally, because the data are derived from a
clinical trial population in which patients with a
poor prognosis and large hematoma were excluded,
there may be concerns of the generalizability of the
ﬁndings.
In summary, these analyses of the INTERACT2
database highlight the adverse prognostic signiﬁcance
of decreased admission eGFRs in patients with ICH,
which appears independent of an effect of hematoma
or perihematomal edema growth. However, early
intensive BP-lowering treatment provides broadly
consistent effects, even in patients with ICH with
decreased eGFRs.
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